Interestingly, in comparison with average remaining evading apoptosis by single COX-2 inhibition of these three tumor types, the combination inhibitions of COX-2+ERBB2, COX-2+ERBB3, COX-2+EGFR and COX-2+PDGFRB (platelet-derived growth factor receptor beta), show clear additive effect for breast and colon tumors, whereas for lung tumor, the combination inhibition of COX-2+EPHB (EPH receptor) and COX-2+FGFR have a clear additive effect. The gene discussed is PDGFRB; the disease is neoplasm.